A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.

The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

The present invention relates to synergistic compositions comprising bromelain, or a proteolytic fraction thereof, and cysteamine or a metabolite, pharmaceutically acceptable salt, solvate or prodrug thereof The invention also relates to methods and uses of such compositions for the treatment of diseases involving mucin.

This invention disclosed herein relates generally to compositions comprising the cysteine protease ananain, a reducing agent and a buffer. Also disclosed generally herein are methods of stabilizing the cysteine protease, ananain while retaining protease activity, as well as methods of activating ananain zymogen for proteolysis.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The membrane polymer matrix contains a hydrophobic polymer in combination with a hydrophilic compound, and the weight ratio of the hydrophobic polymer to the hydrophilic compound within the membrane polymer matrix ranges from about 0.25 to about 200.

The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

An oral fibrinolytic composition comprising the enzymes serrapeptase and nattokinase. The composition treats and/or may prevent fibrosis conditions and their related symptoms in animals, including humans. This composition may further comprise of one or more enzymes, bioflavonoids, vitamins, coenzymes, minerals, probiotics, prebiotics, herbs, excipients and/or combinations thereof. The composition may improve lung capacity, oxygen saturation, vigor, and/or lung function. It may further alleviate dyspnea, limitations and fear caused by dyspnea, cough, phlegm, fatigue, body pain, chest discomfort, anxiety, depression, loss of appetite, and/or respiratory disorders. The composition of serrapeptase and nattokinase and/or one or more additional component may improve immune health, sleep, health-related quality of life (HRQoL), social well-being, health status, mental health and/or exercise capacity. The present disclosure also provides a method for improving or reducing the frequency and severity of fibrosis and related symptoms in a subject having a fibrotic disease.

The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGFR) inhibitor.

A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.

A dry consumable preparation and related methods are disclosed. The preparation has a plurality of excipient particles and at least one of a cannabinoid and a cannabinoid extract, the at least one of the cannabinoid or the cannabinoid extract containing one or more cannabinoids plated to the plurality of excipient particles. The preparation further comprises an effervescence agent, the effervescence agent comprising a carbonate salt, and at least one acid. The carbonate salt comprises sodium, potassium and/or calcium. The at least one acid comprises at least one of citric acid, tartaric acid, lactic, acetic, benzoic, ascorbic, oxalic, tannic, phosphoric, or malic acid. A ratio of the at least one of the carbonate salt to the at least one acid is at least 1:1, the ratio configured to create a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.